SOMALOGIC GETS RIGHTS TO DNA MODIFICATION PATENTS.
"This new DNA modification technology will make our aptamer identification program even more aggressive," stated Patricia K. Scheller, CEO of SomaLogic. "It signifies another advance in SomaLogic's efforts to expand the content of our aptamer arrays and discover protein-based disease signatures."
"By combining the advantages of established aptamer technology with more antibody-like chemical diversity, we can now address the widest possible range of protein targets," added Bruce Eaton, senior director of research at SomaLogic. "Since these technologies have already been optimized, they also provide SomaLogic with clear pathways to commercialization."
Since its founding in 1999, SomaLogic has developed aptamer arrays for multiplexed, quantitative protein measurements. SomaLogic uses these arrays in its protein signature discovery program to identify the complex relationships between proteins, diseases and health. The company is committed to commercializing novel proteomics-based diagnostics that will drive new approaches for screening, diagnosing and managing disease.
SomaLogic is developing novel proteomics systems and applications based on its proprietary aptamer technology. Aptamers are single-stranded DNA and RNA molecules that, like antibodies, can bind to target molecules with high affinity and specificity. Aptamers are identified using the proprietary SELEX process and may offer significant advantages for multiplexed protein measurements. SomaLogic is headquartered in Boulder, Colorado.
For more information, visit http://www.somalogic.com or call 303/625-2066.
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 1, 2004|
|Previous Article:||DYAX/GENZYME PHASE II TRIAL OF DX-88 MEETS ENDPOINT.|
|Next Article:||HYBRIDON'S OLIGONUCLEOTIDES SHOW POTENT ADJUVANT ACTIVITY.|